Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. We show 26 historical shares outstanding datapoints in our GOSS shares outstanding history coverage, used to compute GOSS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing GOSS market cap history over the course of time is important for investors
interested in comparing GOSS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of GOSS versus a peer is one thing; comparing
GOSS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like GOSS can fluctuate over the course of history.
With this page we aim to empower investors researching GOSS by allowing them to research the GOSS market cap history. |
Free GOSS Email Alerts:
Video: The Importance of Market Cap
